ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed... - Seite 2

BAN2401 (Esai/Biogen) and aducanumab (Biogen) appear to target both AB plaque and soluble AB oligomers. Recent clinical trials with both BAN2401 and aducanumab, reporting a dose-related response curve (i.e., higher doses enabling greater efficacy) support the targeting of AB oligomers for the treatment of AD and at the same time indicate that treatment with antibodies also targeting AB plaque is associated with dose-limiting brain swelling in a significant percentage of AD patients. We have shown in multiple preclinical studies that PMN310 has the advantage of selectively targeting toxic AB oligomers, with no "off-target" binding to AB plaque, potentially allowing for the safe administration of higher effective doses of PMN310 compared to BAN2401 or aducanumab. 

According to Dr. Goldstein, "Although both BAN2401 and aducanumab have shown encouraging phase 2 clinical results, the greater selectivity and avoidance of plaque binding with PMN310 may confer significant advantages in the clinic supporting  PMN310 as potential 'best in class' therapy."

IHC is the process of selectively imaging antigens (e.g. proteins) in cells of a tissue section by exploiting the principle of antibodies (such as PMN310, aducanumab, BAN2401) binding specifically to their antigen targets in biological tissues. In the study referred to above, IHC was used to assess binding of AB-directed antibodies to AB plaque in AD brain tissue.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.